Clinical Papers

KEY REFERENCES

• Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial.
  Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al.
  Lancet Oncol. 2014;15(9):966-74.

• International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
  Van Rhee F, Voorhees R, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al.
  Blood. 2018;132(15): 2115-24.

• International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
  Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al.
  Blood. 2017;129(12):1646-57.

• Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
  Van Rhee F, Rossi JF, Simpson D, et al.
  British Journal of Haematology. 2020 Oct. DOI: 10.1111/bjh.17177.

• Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6 directed therapy.
  Mukherjee S, Martiin R, Sande B, et al. Blood Adv. 2021 Sep. DOI: 0.1182/bloodadvances.2021004441..

For clinical paper requests, please contact EUSA Medical Information

To find out more about EUSA Pharma privacy practices view the Privacy Policy